Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JRS-II LRB phase II study of VAC1.2 and VI for newly diagnosed low-risk subset B rhabdomyosarcoma
jRCTs051180200Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, actinomycin D, cyclophosphamide and irinotecan in rhabdomyosarcoma (RMS) and embryonal rhabdomyosarcoma (ERMS), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: event-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
vincristineactinomycin Dcyclophosphamideirinotecan
03
Conditions
rhabdomyosarcoma (RMS)embryonal rhabdomyosarcoma (ERMS)
Beyond the preview
Go deeper on jRCTs051180200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180200.